About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Found 20875 record(s)
Req # A-2021-001225
Adverse Drug Reactions (ADRs) for FUROSEMIDE. Report numbers: E2B_03743360, 000946426, 000937126, E2B_03738509, 000929796, 000932278, E2B_03899283, E2B_03904331, E2B_03755570.Organization: Health Canada
January 2022
Req # A-2021-001246
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-115145-17, Health Canada’s Monitoring Report of Staffing Activities for 2018-2019 and 2019-2020.Organization: Health Canada
January 2022
Req # A-2021-001247
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 19-121772-392.Organization: Health Canada
January 2022
Req # A-2021-001248
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-115132-114.Organization: Health Canada
January 2022
Req # A-2021-001260
Adverse Drug Reaction (ADR) for AGALSIDASE BETA. Report number: E2B_03614299.Organization: Health Canada
January 2022
Req # A-2021-001263
Adverse Drug Reaction (ADR) for HYDROXYCHLOROQUINE SULFATE. Report number: E2B_03702639.Organization: Health Canada
January 2022
Req # A-2021-001264
Adverse Drug Reaction (ADR) for INSULIN LISPRO. Report number: E2B_03868853.Organization: Health Canada
January 2022
Req # A-2021-001295
Adverse Drug Reactions (ADRs) for JANUVIA. Report numbers: 000714551, 000716466, 000716557, 000719315, E2B_02165440, E2B_01738885, 000721859, 000720290.Organization: Health Canada
January 2022
Req # A-2021-001296
Adverse Drug Reactions (ADRs). Report numbers: E2B_02947418, E2B_02403902, E2B_02422874, E2B_02425044, E2B_02403901, E2B_02394795, E2B_02395347, E2B_02629708, E2B_02375698, E2B_03453475, E2B_02136785, E2B_03034112, E2B_02435111, E2B_02436382, E2B_02440745.Organization: Health Canada
January 2022
Req # A-2021-001297
Adverse Drug Reactions (ADRs). Report numbers: E2B_02444666, E2B_03029395, E2B_02467792, E2B_02476722, E2B_02477151, E2B_02477309, E2B_02480194, E2B_03438684, E2B_03181123, E2B_03154815, E2B_03054673, E2B_02491780, E2B_03051085, E2B_02504619, E2B_02511132.Organization: Health Canada
January 2022